Ipamorelin

Mechanism of action in research models

Ipamorelin is a high-affinity agonist of the growth-hormone-secretagogue receptor type 1a (GHSR-1a, also called the ghrelin receptor), the G-protein-coupled receptor (Gq and Gs coupled) that mediates pulsatile GH release from pituitary somatotroph cells. Activation triggers two primary intracellular pathways in somatotroph research models:

1. IP3 / intracellular calcium mobilisation: Gq-coupled GHSR-1a activation leads to phospholipase C (PLC) activation, generation of IP3 and diacylglycerol (DAG), and IP3-mediated release of Ca²⁺ from the endoplasmic reticulum. This calcium flux triggers fusion of GH-containing secretory granules with the plasma membrane and GH exocytosis into the circulation.

2. Adenylyl-cyclase / cAMP pathway: Gs-coupled GHSR-1a activation increases intracellular cAMP via adenylyl cyclase, activating PKA and contributing to the secretory response. This dual-pathway activation produces a potent, supraphysiological GH pulse in research models.

Critically, Ipamorelin’s selectivity is characterised by very low affinity for receptors mediating ACTH and cortisol secretion — a key distinction from GHRP-6, which activates CRH-dependent cortisol pathways at similar concentrations. This selectivity is attributed to the D-2-naphthylalanine substitution at position 3, which optimises GHSR-1a binding without activating the broader melanocortin-receptor family. Downstream of GH release, research has examined the consequent stimulation of hepatic IGF-1 production and body-composition changes in rodent models attributable to GH-IGF-1 axis activation.

Research background and peer-reviewed literature

Ipamorelin was first described by Raun and colleagues from Novo Nordisk in 1998 in a landmark publication in the European Journal of Endocrinology. This study established its pharmacological profile — high-potency GHSR-1a agonism with selective GH release and no significant ACTH/cortisol activation — in in-vitro pituitary cell-culture models and in-vivo rat models, defining the gold-standard selectivity profile against which subsequent GHRPs are compared.

Research combining Ipamorelin with GHRH analogues (particularly CJC-1295) has been extensively documented. The rationale — simultaneous activation of both GHRH receptor and GHSR-1a on somatotrophs — produces synergistic GH-release amplitudes in pituitary cell models, and this combination has become one of the most common protocols in GH-secretagogue research. Studies in ageing rodent models have examined Ipamorelin’s effects on age-related GH deficiency, body composition, and bone mineral density.

Comparison vs. other GHRPs (research selectivity)

Reconstitution and storage protocol

1. Equilibrate lyophilized vial to room temperature.
2. Reconstitute with sterile bacteriostatic water or another validated research diluent; a common research concentration is 1 mg/mL (e.g., 5 mL into a 5 mg vial).
3. Introduce diluent slowly along the vial wall; swirl gently to dissolve.
4. Ipamorelin is readily water-soluble; complete dissolution should occur within 1–2 minutes.

Storage: lyophilized at −20 °C, desiccated, light-protected (stable ≥24 months). Reconstituted at 4 °C for up to 28 days in bacteriostatic water; aliquot to −80 °C for extended storage.